Company profile
ALX ONCOLOGY HOLDINGS INC
NASDAQ:ALXOBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| EVORPACEPT | phase2_3 | — | 8 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07085091 | phase1 | recruiting | 2025-08-18 | 2027-06-01 | ALX Oncology Inc. | A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors |
| NCT04417517 | phase1 | terminated | 2020-10-02 | 2025-01-17 | ALX Oncology Inc. | A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02) |
| NCT05524545 | phase1 | completed | 2022-11-02 | 2025-06-27 | ALX Oncology Inc. | A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07) |
| NCT04755244 | phase1 | terminated | 2021-05-05 | 2023-05-05 | ALX Oncology Inc. | A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) |
| NCT05002127 | phase2_3 | active_not_recruiting | 2022-01-15 | 2024-05-24 | ALX Oncology Inc. | A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) |
FDA applications (0)
No records yet.